Source: Eur Respir J, 58 (6) 2101221; 10.1183/13993003.01221-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Pauline Henrot, Fabien Beaufils, Matthieu Thumerel, Edmée Eyraud, Augustin Boudoussier, Hugues Begueret, Elise Maurat, Pierre-Olivier Girodet, Roger Marthan, Patrick Berger, Isabelle Dupin, Maéva Zysman. Circulating fibrocytes as a new tool to predict lung cancer progression after surgery?. Eur Respir J, 58 (6) 2101221; 10.1183/13993003.01221-2021

Member's Comments

No comment yet.

Related content which might interest you: Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015 Issues other than tissue: non-invasive biomarkers of early stage lung cancer Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules? Year: 2020 Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008 Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Are serum leptin levels a prognostic factor in advanced lung cancer? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? Source: Eur Respir J 2014; 43: 1240-1242 Year: 2014 Role of biomarkers for early detection of lung cancer and chemoprevention Source: Eur Respir J 2002; 19: 1151-1158 Year: 2002 The value of adiponectin as an inflammatory marker in lung cancer? Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Evolution in the diagnostic approach to lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 Why can initial treatment of localised lung cancer fail? Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent Year: 2007 Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 The invasive diagnostics of lung cancer with secondary inflammatory changes Source: Eur Respir J 2006; 28: Suppl. 50, 81s Year: 2006 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018